DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Active ingredient: Adalimumab - Brands, Medical Use, Clinical Data

Brands, Medical Use, Clinical Data

Drug Category

  • Antirheumatic Agents
  • Immunomodulatory Agents

Dosage Forms

  • Solution

Brands / Synonyms

Humira; Humira (Abbott Laboratories) ; Ig gamma-1 chain C region

Description

Anti-TNF antibody, expressed in mammalian cell culture, 1330 residues, MW=148 kD. Humira was created using phage display technology resulting in an antibody with human derived heavy and light chain variable regions and human IgGl:K constant regions. It is produced by recombinant DNA technology in a mammalian cell expression system

Indications

For treatment of rheumatoid arthritis

Pharmacology

Used in the treatment of rheumatoid arthritis. Elevated levels of TNF are found in the synovial fluid of rheumatoid arthritis patients and play an important role in both the pathologic inflammation and the joint destruction that are hallmarks of the disease. Adalimumab binds specifically to TNF-alpha and blocks its general cytokine effects, thereby reducing TNF-induced inflammation and halting the joint destruction.

Mechanism of Action

Adalimumab binds to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also lyses surface TNF expressing cells in vitro in the presence of complement.

Absorption

Not Available

Toxicity

Not Available

Biotrnasformation / Drug Metabolism

Most likely removed by opsonization via the reticuloendothelial system.

Contraindications

Not Available

Drug Interactions

Not Available

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014